Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage –. – Data Featured in an Oral Presentation at ...
Wednesday 22 May 2019
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage - GlobeNewswire
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage GlobeNewswire
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment